Karo Pharma (OM:KARO) - Aktienkurs, Nachrichten und Analyse

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

KARO Aktienübersicht

Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, Germany, Italy, rest of Europe, the United States, and internationally.

Über das Unternehmen

KARO grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	0/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	1/6
Dividenden	0/6

Belohnungen

Risikoanalyse

Earnings have declined by 46.5% per year over past 5 years

Interest payments are not well covered by earnings

Shareholders have been diluted in the past year

Karo Pharma AB (publ) Wettbewerber

Camurus

OM:CAMX

kr33.7b

Swedencare

OM:SECARE

kr9.9b

Calliditas Therapeutics

OM:CALTX

kr11.0b

Orexo

OM:ORX

kr723.4m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Karo Pharma
Historische Aktienkurse
Aktueller Aktienkurs	kr60.70
52-Wochen-Hoch	kr62.40
52-Wochen-Tief	kr49.25
Beta	0.10
11 Monat Veränderung	0.50%
3 Monate Veränderung	1.17%
1 Jahr Veränderung	4.84%
33 Jahre Veränderung	56.85%
5 Jahre Veränderung	57.66%
Veränderung seit IPO	-97.64%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	KARO	SE Pharmaceuticals	SE Markt
7D	0.5%	3.4%	0.7%
1Y	4.8%	82.6%	16.6%

Rendite im Vergleich zur Industrie: KARO exceeded the Swedish Pharmaceuticals industry which returned -23.2% over the past year.

Rendite vs. Markt: KARO exceeded the Swedish Market which returned -24.8% over the past year.

Preisvolatilität

Is KARO's price volatile compared to industry and market?
KARO volatility
KARO Average Weekly Movement	0.4%
Pharmaceuticals Industry Average Movement	10.1%
Market Average Movement	5.9%
10% most volatile stocks in SE Market	12.8%
10% least volatile stocks in SE Market	3.5%

Stabiler Aktienkurs: KARO has not had significant price volatility in the past 3 months.

Volatilität im Zeitverlauf: KARO's weekly volatility (0%) has been stable over the past year.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1987	225	Christoffer Lorenzen	www.karopharma.com

Karo Pharma AB (publ)'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Karo Pharma im Vergleich zum Marktanteil des Unternehmens?
KARO grundlegende Statistiken
Marktanteil	kr16.59b
Gewinn(TTM)	-kr189.85m
Umsatz(TTM)	kr3.47b

4.8x

Kurs-Umsatz-Verhältnis

-87.4x

Kurs-Gewinn-Verhältnis

Ist KARO zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
KARO Gewinn- und Verlustrechnung (TTM)
Einnahmen	kr3.47b
Kosten der Einnahmen	kr1.50b
Bruttogewinn	kr1.96b
Sonstige Ausgaben	kr2.15b
Umsatz	-kr189.85m

Zuletzt gemeldete Gewinne

Jun 30, 2022

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.69
Bruttomarge	56.67%
Nettogewinnspanne	-5.48%
Schulden/Eigenkapital-Verhältnis	104.8%

Wie hat sich KARO auf lange Sicht entwickelt?

Historische Performance und Vergleiche

This company listing is no longer active

KARO Aktienübersicht

Belohnungen

Risikoanalyse

Karo Pharma AB (publ) Wettbewerber

OM:CAMX

kr33.7b

OM:SECARE

kr9.9b

OM:CALTX

kr11.0b

OM:ORX

kr723.4m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Nasdaq Approves Karo Pharma's Application for De-Listing

Karo Intressenter AB made a public cash offer to acquire remaining 13.6% stake in Karo Pharma AB (publ) (OM : KARO) for SEK 2.2 billion.

Karo Pharma AB (publ) (OM:KARO) completed the acquisition of E45 brand and related sub-brands from Reckitt Benckiser Group plc (LSE:RKT).

Karo Pharma AB (publ) to Report Fiscal Year 2021 Final Results on Apr 12, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Karo Pharma AB (publ) to Report Nine Months, 2022 Results on Oct 25, 2022

Recent updates

Nasdaq Approves Karo Pharma's Application for De-Listing

Karo Intressenter AB made a public cash offer to acquire remaining 13.6% stake in Karo Pharma AB (publ) (OM : KARO) for SEK 2.2 billion.

Karo Pharma AB (publ) (OM:KARO) completed the acquisition of E45 brand and related sub-brands from Reckitt Benckiser Group plc (LSE:RKT).

Karo Pharma AB (publ) to Report Fiscal Year 2021 Final Results on Apr 12, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Karo Pharma AB (publ) to Report Nine Months, 2022 Results on Oct 25, 2022

Karo Pharma AB (publ) to Report Fiscal Year 2021 Results on Feb 25, 2022

Karo Pharma AB (publ) completed the acquisition of Sylphar N.V. from Vendis Capital Management, Robin List, Sylphar's founder and others.

Karo Pharma AB (publ) entered into an agreement to acquire Sylphar N.V. from Vendis Capital Management, Robin List, Sylphar's founder and others for €300 million.

Third quarter 2021 earnings released: EPS kr0.26 (vs kr0.013 loss in 3Q 2020)

Karo Pharma (STO:KARO) Has No Shortage Of Debt

Second quarter 2021 earnings released: kr0.095 loss per share (vs kr0.11 profit in 2Q 2020)

Is Karo Pharma (STO:KARO) A Risky Investment?

Evolan Pharma AB acquired Portfolio Consisting of 12 Brands from Karo Pharma AB (publ) (OM:KARO).

Independent Chairman of the Board Bo Hansen has left the company

First quarter 2021 earnings released: EPS kr0.24 (vs kr0.39 in 1Q 2020)

Full year 2020 earnings released: EPS kr0.37 (vs kr0.051 in FY 2019)

Karo Pharma (STO:KARO) Seems To Be Using A Lot Of Debt

Karo Pharma's (STO:KARO) Strong Earnings Are Of Good Quality

Is Karo Pharma AB (publ)'s (STO:KARO) 1.5% ROE Worse Than Average?

Full year 2020 earnings released: EPS kr0.37 (vs kr0.051 in FY 2019)

Karo Pharma AB (publ), Annual General Meeting, Apr 21, 2021

Karo Pharma AB (publ) (OM:KARO) acquired European OTC brand portfolio of Teva Pharmaceutical Industries Limited (NYSE:TEVA) for €84 million.

Did You Participate In Any Of Karo Pharma's (STO:KARO) Fantastic 144% Return ?

New 90-day low: kr48.85

New 90-day low: kr51.10

Karo Pharma AB (publ) to Report First Half, 2021 Results on Jul 22, 2021

New 90-day low: kr58.10

New 90-day low: kr61.10

J2L Holding AB agreed to acquire Swereco AB from Karo Pharma AB (publ) (OM:KARO) for SEK 150 million.

Third quarter earnings released

EQT VIII, a fund managed by EQT Partners completed the acquisition of 66.5% stake in Karo Pharma AB (publ) (OM:KARO) for SEK 4.1 billion.

Karo Pharma AB (publ) (OM:KARO) acquired remaining Pevaryl® brand portfolio from Cilag GmbH International for €58 million.

Karo Pharma AB (publ) to Report Fiscal Year 2020 Results on Feb 18, 2021

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

Karo Pharma AB (publ)'s Grundlagenzusammenfassung

4.8x

-87.4x

Erträge &amp; Einnahmen

Erträge & Einnahmen